Chugai Venture Fund

Leal Therapeutics is a Massachusetts-based company focused on developing innovative therapeutics aimed at addressing significant and unmet needs in central nervous system disorders. By leveraging precision medicine, Leal Therapeutics seeks to provide effective treatment options for patients suffering from various neurological conditions. The company's commitment to advancing therapeutic solutions is reflected in its dedication to improving patient outcomes through targeted interventions.

Stylus Medicine is a Cambridge, Massachusetts biotechnology company focused on developing disease-treating therapies. It advances next-generation treatments by applying genome engineering and chromatin regulation techniques to create delivery methods for enzymes and drugs aimed at enabling targeted, in vivo gene editing. The goal is to enable insertion of sizeable genetic sequences into the human genome to pursue permanent cures for patients.